Amycinpyrifya-sensitive lipid regime agent Phase III clinical lysa-critical.

Drug Source Analysis Seven years ago CLSN made the small company famous for working with Haizheng in the Chinese-language pharmaceutical industry, when a phase 3 clinical failure called HEAT cost Hai a $5 million down payment in a short period of timeLater, the subgroup analysis of the HEAT trial by CLSN found that a population (medium-sized tumors, single lesions, 45 minutes of RFA treatment) seemed to be more sensitive to ThermoDox, reducing the risk of death by up to 50%, and then began a phase III clinical, OPTIMA, for this populationBut this subgroup analysis is very unreliable, as sugar cane to be frosted, radon to be original, it seems to be related, real coincidenceOf course, the conclusions of clinical observation are not always unreliable, and many new drugs are also starting with clinical occasional observations, such as the recently listed Dravet drug FinteplaOnly based on this subgroup analysis is more likely to be false than the therapeutic hypothesis supported by systematic dataThe technique itself is slightly higher than body temperature based on the phase change temperature of certain lipids, so the system is slower to release at 37 degreesBut if you raise the temperature in the lesions tissue, you will selectively release the drug in the lesions, the same idea as photosensitive ADCs or even ADCs themselvesRFA is already a physical technique for treating liver cancer, using electrodes to raise temperatures locally in the lesionsAnyway, the patient's liver will be heated, plus a heat-sensitive preparation burden is very small, so the choice of this indication is very cleverIn addition, lipids may have accumulated in tumor tissue through the EPR effect, and the liver is an ideal place for these nano-preparationsIt is said that the EPR effect increases after heating, and cell drink ingress is more effectiveCLSN claims the drug is 25 times more abundant in the liver, but an article says the technique in pig models allows amycin to accumulate three times as much in the liver as peripheral tissuesTriple doesn't sound high, but these traditional chemotherapy treatment windows are usually small, if not 1 or lessThe effective dose of the Dorseytha-seok preclinical model is accurate to a single digit after the decimal point, so 3 times is a huge increaseOf course, the accumulation of lesions does not mean that the treatment window is expandedFirst, even liver cancer patients' livers are still dominated by normal cells, so there are local toxicity problemsSecond, killing in situ cancer cells may not necessarily be transformed into survival advantages, even if radiotherapy is sometimes through the effects of the whole body Another factor is liver cancer itself, which is a difficult tumor to treat In particular, first-line therapies have not progressed for many years, and this year The first-line therapy has been a multikinase inhibitor sorafinini for more than a decade before Tecentriq/Bevalsasinga is on the market, although this is a high-risk solid tumor About 50% of liver cancer is caused by chronic hepatitis B, so the cure of hepatitis B can indirectly reduce the death toll from liver cancer Now targeting the main antigen mRNA of hepatitis B RNAi drug in the early clinical display of more than 10% of the Ao anti-yang rate, a non-specific nucleic acid therapy is said to produce 50% of the secondary clinical rate of transcurrent, but the mechanism is more vague Another major cause of liver cancer is NASH, an area that has failed many times in recent years but has several mechanisms that show good prospects such as GLP, FGF21, and thyroid receptor agonists NASH and hepatitis B are also not good to treat, but than the late liver cancer may still be easy, so the treatment of Wei Zhao, cure these two diseases is a reliable strategy